GlassScriptPhysician profile
Karen S Staack
NPI 1831161587
$3,423.95
in general payments reported to CMS, 2019-2025
42 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $605 · 2021: $704 · 2022: $558 · 2023: $372 · 2024: $431 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.73 | 2019-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $340.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $297.78 | 2019-2025 | |
| Amarin Pharma, INC. | $247.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $229.36 | 2019-2025 | Airsupra |
| Amgen INC. | $228.31 | 2019-2023 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $212.01 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Aimmune Therapeutics, INC. | $97.54 | 2024 | |
| Biogen, INC. | $85.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.45 | 2020-2023 | |
| Upsher-Smith Laboratories LLC | $79.43 | 2020-2021 | |
| Ibsa Pharma INC. | $70.54 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.11 | 2022 | |
| Inspire Medical Systems, INC. | $65.04 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $64.23 | 2019-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Staack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.